STOCK TITAN
  1. Home
  2. Sec-filings
  3. DXCM
  4. [Form 4] DEXCOM INC Insider Trading Activity

DXCM Form 4: Collins Trust sold 3,948 shares; 37,994 remain

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Dexcom (DXCM) insider activity: Director Richard A. Collins, through the Richard A. Collins Revocable Trust, sold 3,948 shares of common stock on 11/10/2025 at $55.17 per share, pursuant to a Rule 10b5-1 plan adopted on August 7, 2025.

Following the sale, 37,994 shares are beneficially owned indirectly by the Trust. In addition, 5,074 unvested RSUs granted on May 8, 2025 will vest on the earlier of the one-year grant anniversary or DexCom’s 2026 Annual Meeting of Stockholders.

Positive

  • None.

Negative

  • None.
Insider Collins Richard Alexander
Role Director
Sold 3,948 shs ($218K)
Type Security Shares Price Value
Sale Common Stock 3,948 $55.17 $218K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 37,994 shares (Indirect, by Trust); Common Stock — 5,074 shares (Direct)
Footnotes (1)
  1. On August 7, 2025, the Richard A. Collins Revocable Trust (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. Shares are held by the Richard A. Collins Revocable Trust, with respect to which the reporting person is a trustee. Represents unvested restricted stock units which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Collins Richard Alexander
(Last) (First) (Middle)
6340 SEQUENCE DRIVE
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/10/2025 S 3,948(1) D $55.17 37,994 I by Trust(2)
Common Stock 5,074(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On August 7, 2025, the Richard A. Collins Revocable Trust (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.
2. Shares are held by the Richard A. Collins Revocable Trust, with respect to which the reporting person is a trustee.
3. Represents unvested restricted stock units which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Richard Alexander Collins 11/10/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction was reported for DXCM?

Director Richard A. Collins sold 3,948 shares of common stock on 11/10/2025 at $55.17 per share.

Was the DXCM sale under a Rule 10b5-1 plan?

Yes. The Trust adopted a 10b5-1 plan on August 7, 2025, and the shares were sold pursuant to that plan.

How many DXCM shares does the reporting person hold after the sale?

Following the sale, 37,994 shares are beneficially owned indirectly by the Richard A. Collins Revocable Trust.

What is the reporter’s relationship to Dexcom (DXCM)?

The reporting person is a Director of Dexcom, Inc.

Are there unvested RSUs disclosed for DXCM?

Yes. There are 5,074 unvested RSUs granted on May 8, 2025, vesting on the earlier of the one-year anniversary or the 2026 Annual Meeting.

How were the shares held before the sale?

The sold shares were held by the Richard A. Collins Revocable Trust, for which the reporting person is a trustee.